11th International Conference on Cryptococcus and Cryptococcosis (ICCC)

摘要 该提案要求部分支持第11届国际隐球菌会议， 隐球菌病（ICCC）将于2022年1月10日至14日在乌干达坎帕拉举行。隐球菌病 全球15%的艾滋病相关死亡。隐球菌脑膜炎仍然是最常见的神经感染 在撒哈拉以南非洲的所有成年人中，艾滋病毒仍然是越来越多的非艾滋病毒感染者的主要威胁。 免疫力低下的人。 ICCC的广泛和长期目标是汇集世界领先的研究人员， 扩大领域，促进跨学科的讨论，研究和临床合作，以提高我们的 了解隐球菌的致病机制和隐球菌病的最佳治疗。 这次会议的具体目标是召集主要专家，他们的专门知识涉及关键领域， 在这个领域内的领域，以及早期的职业生涯和初级研究人员，学生和博士后。我们 预计接待300名与会者。该计划将分为17个会议，涵盖不同的 病原体的性质和特点以及宿主的易感性和免疫力，强调 是什么让一个正常的宿主突然对这种疾病易感重要的是，会议将提供 广泛覆盖当前和新型抗真菌药物-从临床前开发项目到 正在进行/未来的临床试验。初级研究人员、研究生和博士后研究员的摘要 将被列入口头报告的候选人名单。会议将举办两次海报会议 这将使所有参与者都能对这些主题作出积极贡献。在17个会话块中，12个块 将同时举行会议，以允许较小的工作组开会，更多的学生/学员 介绍他们的摘要。R13资源将用于支持研究生参加旅行补助金 学生，特别是来自美国和非洲的少数民族学者，他们提交了摘要。 我们将在选择发言人和组织会议方面争取妇女和少数民族的平等。 委员会的三名共同主席中有两名是妇女或少数民族。我们至少要瞄准 全体会议发言人中约40%为妇女，约10%为代表不足的少数民族。将提供托儿服务。 第11届ICCC是重要的，因为重点是一个重要的传染病折磨双方 免疫力低下和免疫力正常的人。这是唯一一次这样的会议， 研究隐球菌病的基础科学家和临床研究者。这是第一次 会议将在非洲举行，目标：1）建立新的美国-非洲转化研究 合作; 2）确定重要的临床，转化和基础科学研究议程，以建立 新的预防和治疗策略的新途径。

ABSTRACT This proposal requests partial support for the 11th International Conference on Cryptococcus and Cryptococcosis (ICCC) to be held in Kampala, Uganda, January 10-14, 2022. Cryptococcosis accounts for 15% of AIDS-related deaths globally. Cryptococcal meningitis remains the most common neuroinfection among all adults in Sub-Saharan Africa and continues to be a major threat to a growing number of non-HIV immunocompromised persons. The broad and long-term goal of this ICCC is to bring together the world's leading researchers in this expanding field to foster cross-disciplinary discussions, research, and clinical collaborations to enhance our understanding of the mechanisms of Cryptococcus pathogenicity and best management of cryptococcosis. The specific aims of this meeting will be to convene leading experts whose expertise covers critical areas within this field, as well as early career and junior investigators, students, and postdocs. We anticipate hosting 300 participants. The program will be structured into 17 sessions covering the diverse properties and characteristics of the pathogen as well as host susceptibility and immunity, emphasizing what makes a normal host suddenly susceptible to this disease. Importantly, the conference will provide ample coverage of current and novel antifungals – ranging from pre-clinical development programs through ongoing/future clinical trials. Abstracts from junior investigators, graduate students, and postdoctoral fellows will be included among those selected for oral presentation. The conference will host two poster sessions which will permit all participants to actively contribute to these topics. Of the 17 session blocks, 12 blocks will be concurrent sessions to allow for smaller working groups to meet and more students / trainees to present their abstracts. The R13 resources will go towards supporting travel grant participation by graduate students and specifically under-represented minority scholars from US and Africa who present abstracts. We will seek parity with respect to women and minorities in the selection of speakers and organizing committee, starting with 2 of the 3 ICCC co-chairs being a woman or a minority. We will target at least ~40% of plenary speakers to be women and ~10% under-represented minorities. Childcare will be provided. The 11th ICCC is significant because focuses on an important infectious disease afflicting both immunocompromised and immunocompetent people. This is the only such conference that brings together basic scientists and clinical investigators who investigate cryptococcosis. This is the first time the conference will be held in Africa with objectives: 1) to build new US-African translational research collaborations; 2) to define the important clinical, translational, and basic science research agenda to forge new avenues for novel prevention and treatment strategies.